MI that incorporated perioperative and longer term mortality, complications, patency, reinterventions, and their associated costs.
They reported that the endovascular therapy cost more
for patients less than 60 years of age, but the incremental
cost effectiveness ratio was less than $60,000 per
quality-adjusted life-year. For patients 60 years of age
and older, the endovascular approach was preferred
because the effectiveness was greater and the costs
